Fluticasone Propionate And Salmeterol Powder, Metered
Product Images NDC 63629-8811

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 63629-8811). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fp Chem Structure (Fluticasone Propionate Salmeterol Inhalation Powde 1)

Chemical structure of Fluticasone Propionate, illustrating the arrangement of atoms including oxygen, sulfur, fluorine, carbon, and hydrogen in the molecular framework.*

FDA Label Image

Figure 8 (Fluticasone Propionate Salmeterol Inhalation Powde 10)

A line graph depicting mean change in FEV1 over 12 hours comparing different treatments: Fluticasone Propionate and Salmeterol (FS) MDPI at 232 mcg and 113/14 mcg doses, Fluticasone Propionate (FP) MDPI at 232 mcg and 113 mcg doses, and placebo. The x-axis represents time in hours, and the y-axis shows change in FEV1. Multiple lines indicate varying responses over the 12-hour period post-baseline.*

FDA Label Image

Teva Logo (Fluticasone Propionate Salmeterol Inhalation Powde 11)

FDA Label Image

Teva Logo (Fluticasone Propionate Salmeterol Inhalation Powde 12)

FDA Label Image

Figurr A (Fluticasone Propionate Salmeterol Inhalation Powde 13)

Illustration of a Fluticasone Propionate and Salmeterol metered powder inhaler showing labeled parts including the vent, mouthpiece, yellow cap, and dose counter.*

FDA Label Image

Figure B (Fluticasone Propionate Salmeterol Inhalation Powde 14)

Illustration showing two circular indicators for a respiratory metered powder inhaler. One indicator labeled "Inhaler Full" shows the dose counter at 60 doses. The other indicator labeled "Inhaler Empty" shows the dose counter at 0 doses with a red background, indicating no doses remaining.*

FDA Label Image

Figure C (Fluticasone Propionate Salmeterol Inhalation Powde 15)

An instructional illustration showing a person holding a metered dose inhaler and pressing down on the mouthpiece cover until a 'click' sound is indicated, demonstrating how to prepare or open the inhaler device for use.*

FDA Label Image

Figure C (Fluticasone Propionate Salmeterol Inhalation Powde 16)

An instructional diagram showing correct and incorrect methods for using a yellow protective cap on a metered powder inhaler device. The correct method involves inserting the cap onto the inhaler while holding it vertically. Incorrect methods include attaching the cap sideways or applying it while holding the inhaler horizontally.*

FDA Label Image

Breathe Out Image (Fluticasone Propionate Salmeterol Inhalation Powde 17)

Illustration showing a profile of a human face exhaling or inhaling with dotted lines representing airflow or inhaled medication particles moving in or out of the mouth.*

FDA Label Image

Figure F (Fluticasone Propionate Salmeterol Inhalation Powde 18)

An instructional illustration showing a person using a metered dose inhaler. A hand holds the inhaler with a yellow protective cap removed, positioned close to the person's mouth for inhalation. The image highlights proper inhaler placement for respiratory drug administration.*

FDA Label Image

Figure G (Fluticasone Propionate Salmeterol Inhalation Powde 19)

An illustration showing a close-up of the mouthpiece and vent area of a metered dose inhaler. The vent is clearly labeled with an arrow pointing to a small opening above the inhaler mouthpiece, which is yellow in color.*

FDA Label Image

Salmeterol Chem Structure (Fluticasone Propionate Salmeterol Inhalation Powde 2)

Chemical structure of Fluticasone Propionate and Salmeterol, showing the detailed molecular arrangement of atoms and bonds characteristic of these active ingredients used in respiratory inhalation powder formulations.*

FDA Label Image

Figure H (Fluticasone Propionate Salmeterol Inhalation Powde 20)

Illustration showing a hand holding a dry powder inhaler and another hand opening the yellow cap by flipping it upwards, demonstrating how to access the inhaler mouthpiece for use.*

FDA Label Image

Teva Logo (Fluticasone Propionate Salmeterol Inhalation Powde 21)

FDA Label Image

Figure 1 (Fluticasone Propionate Salmeterol Inhalation Powde 3)

This figure shows two side-by-side dot plots with 95% confidence intervals representing differences from placebo in two clinical trials (Trial 201 and Trial 202) for fluticasone propionate at various metered doses (mcg) delivered via MDPI and DPI inhaler devices, with doses labeled along the x-axis and difference values on the y-axis.*

FDA Label Image

Figure 2 (Fluticasone Propionate Salmeterol Inhalation Powde 4)

A line graph displaying baseline-adjusted FEV1 (mL) over time (hours) for multiple formulations and dosages of Fluticasone Propionate and Salmeterol (FS MDPI and FS DPI) as well as Fluticasone Propionate MDPI. The graph compares lung function changes up to 12 hours following inhalation, showing different dose responses over time.*

FDA Label Image

Figure 3 (Fluticasone Propionate Salmeterol Inhalation Powde 5)

A line graph showing mean change in FEV1 (L) over a 12-week period for different doses of Fluticasone Propionate and Salmeterol Metered Dose Inhaler (MDPI) compared to placebo. The graph includes data series for FS MDPI 113 mcg/14 mcg, FS MDPI 55 mcg/14 mcg, FP MDPI 113 mcg, FP MDPI 55 mcg, and placebo, with sample sizes noted at each timepoint.*

FDA Label Image

Figure 4 (Fluticasone Propionate Salmeterol Inhalation Powde 6)

A line graph depicting the mean change in FEV1 (in liters) over 12 hours following baseline on day 1. The graph compares five groups: FS MDPI 113 mcg/14 mcg, FS MDPI 55 mcg/14 mcg, FP MDPI 113 mcg, FP MDPI 55 mcg, and placebo. Each group is represented by distinct markers and lines to show their respective FEV1 changes over time.*

FDA Label Image

Figure 5 (Fluticasone Propionate Salmeterol Inhalation Powde 7)

This is a line graph depicting the mean change in FEV1 (liters) over 12 hours for different formulations and doses of Fluticasone Propionate and Salmeterol metered dose inhalers (MDPI), compared with placebo. The graph includes groups with FS MDPI 113 mcg/14 mcg, FS MDPI 55 mcg/14 mcg, FP MDPI 113 mcg, FP MDPI 55 mcg, and placebo, measured at baseline and Week 12.*

FDA Label Image

Figure 6 (Fluticasone Propionate Salmeterol Inhalation Powde 8)

A line graph showing mean change in FEV1 over 12 weeks for five treatment groups: FS MDPI 232 mcg/14 mcg, FS MDPI 113 mcg/14 mcg, FP MDPI 232 mcg, FP MDPI 113 mcg, and placebo. The x-axis represents time in weeks, and the y-axis represents the change in FEV1 in liters. Patient numbers at various weeks are listed below the x-axis for each group.*

FDA Label Image

Figure 7 (Fluticasone Propionate Salmeterol Inhalation Powde 9)

A line graph showing mean change in FEV1 (L) over 12 hours post-dose on Day 1 baseline. It compares five groups: FS MDPI 232 mcg/14 mcg, FS MDPI 113 mcg/14 mcg, FP MDPI 232 mcg, FP MDPI 113 mcg, and placebo, illustrating differences in respiratory function response over time.*

FDA Label Image

Label (Lbl636298811)

Label for Fluticasone Propionate and Salmeterol Inhalation Powder containing 55 mcg of fluticasone propionate and 14 mcg of salmeterol per metered dose. The label shows the product's NDC 63629-8811-1, indicates 60 metered inhalations (0.45 g) per container, and is labeled for prescription use only. It includes storage instructions and is relabeled by Bryant Ranch Prepack, Inc., Burbank, CA.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.